G N Thalmann
Overview
Explore the profile of G N Thalmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Adsan O, Cecchini M, Bisoffi M, Wetterwald A, Klima I, Studer U, et al.
BJU Int
. 2002 Sep;
90(6):579-85.
PMID: 12230621
Objective: To evaluate the perioperative gene-specific primed nested reverse transcription-polymerase chain reaction (RT-PCR) for prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) for staging patients undergoing radical prostatectomy and predicting...
22.
Scholz M, Zehender M, Thalmann G, Borner M, Thoni H, Studer U
Ann Oncol
. 2002 Feb;
13(1):121-4.
PMID: 11863093
Background: The origin of extragonadal retroperitoneal germ cell tumors remains controversial. Whether they develop primarily in the retroperitoneum or whether they are metastases of a primary testicular tumor has long...
23.
Schmidt J, Madersbacher S, Hochreiter W, Thalmann G, Studer U
J Urol
. 2001 Nov;
166(6):2315-6.
PMID: 11696769
No abstract available.
24.
Mills R, Turner W, Fleischmann A, Markwalder R, Thalmann G, Studer U
J Urol
. 2001 Jul;
166(1):19-23.
PMID: 11435814
Purpose: We evaluate the outcome in patients with node positive bladder cancer with particular reference to the effect of individual characteristics of positive nodes on survival after meticulous pelvic lymphadenectomy...
25.
Thalmann G, Sermier A, Rentsch C, Mohrle K, Cecchini M, Studer U
J Urol
. 2000 Nov;
164(6):2129-33.
PMID: 11061941
Purpose: We evaluate the predictive value of urinary cytokine levels of interleukin (IL) 8 and 18 for response in patients receiving intravesical bacillus Calmette-Guerin (BCG) for prevention of recurrences of...
26.
Thalmann G, Sikes R, Wu T, Degeorges A, Chang S, Ozen M, et al.
Prostate
. 2000 Jul;
44(2):91-103 Jul 1;44(2).
PMID: 10881018
Background: Clinically, the lethal phenotypes of human prostate cancer are characterized by their progression to androgen-independence and their propensity to form osseous metastases. We reported previously on the establishment of...
27.
Thalmann G, Sikes R, Devoll R, Kiefer J, Markwalder R, Klima I, et al.
Clin Cancer Res
. 1999 Sep;
5(8):2271-7.
PMID: 10473115
Human prostate cancer has the propensity to metastasize to the bone where reciprocal cellular interactions between prostate cancer and bone cells are known to occur. Osteopontin (OPN), a noncollagenous bone...
28.
Thalmann G, Graber S, Bitton A, Burkhard F, Gruenig O, Studer U
J Urol
. 1999 Jul;
162(2):387-93.
PMID: 10411044
Purpose: We prospectively evaluated a decrease in outflow obstruction caused by benign prostatic hyperplasia (BPH) with second generation thermotherapy. Materials And Methods: Transurethral microwave therapy was given with local anesthesia...
29.
Wu T, Sikes R, Cui Q, Thalmann G, Kao C, Murphy C, et al.
Int J Cancer
. 1998 Aug;
77(6):887-94.
PMID: 9714059
LNCaP lineage-derived human prostate cancer cell lines C4-2 and C4-2B4 acquire androgen independence and osseous metastatic potential in vivo. Using C4-2 and C4-2B4 the goals of the current investigation were...
30.
Stearns M, Ware J, Agus D, Chang C, Fidler I, Fife R, et al.
Prostate
. 1998 Jul;
36(1):56-8.
PMID: 9650917
No abstract available.